drugset / Trial / NCT00592930

Olanzapine in the Treatment of Anorexia Nervosa

NCT00592930

Phase 4 Completed 20 enrolled Northwell Health Eli Lilly and Company · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study compared 10 weeks of treatment with olanzapine versus placebo in adolescent females with anorexia nervosa-restricting type who were undergoing acute treatment on an inpatient unit or a day hospital program that specializes in the treatment of eating disorders.

Timeline

Start
2000-06
Primary completion
2004-12
Completion
2004-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Olanzapine Small molecule 2.5 mg Oral
Subject Olanzapine Small molecule 15 mg Oral

Indications